J Rolski
Overview
Explore the profile of J Rolski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roila F, Rolski J, Ramlau R, Dediu M, Russo M, Bandekar R, et al.
Ann Oncol
. 2009 Jun;
20(11):1867-73.
PMID: 19541792
Background: Casopitant mesylate is a novel, oral neurokinin-1 receptor antagonist with demonstrated antiemetic efficacy. We conducted a randomized, double-blind, controlled phase II trial to evaluate three casopitant doses as part...
2.
Tan E, Rolski J, Grodzki T, Schneider C, Gatzemeier U, Zatloukal P, et al.
Ann Oncol
. 2009 Mar;
20(7):1249-56.
PMID: 19276396
Background: The study compared the efficacy of a first-line treatment with day 1 i.v. vinorelbine (NVBiv) and day 8 oral vinorelbine (NVBo) versus docetaxel (DCT) in a cisplatin-based combination in...
3.
Pawlicki M, Rolski J, Zaluski J, Siedlecki P, Ramlau C, Tomzak P
Oncologist
. 2002 Jun;
7(3):205-9.
PMID: 12065792
Purpose: The combination of vinorelbine and doxorubicin, two very active drugs in metastatic breast cancer, has demonstrated impressive results in terms of efficacy, at the price of cardiac toxicity (10%...
4.
Pawlicki M, Rolski J, Zemelka T, Utych G, Wiczynska B, Rysz B
Przegl Lek
. 2001 Jul;
58(2):59-60.
PMID: 11475843
Twenty women with advanced breast cancer were treated with Docetaxel. In 50% of cases partial remission with median duration of 7.1 months was obtained. The median survival time was 18...
5.
Rolski J, Pawlicki M
Ginekol Pol
. 1998 Nov;
69(7):586-9.
PMID: 9810419
47 patients with advanced ovarian cancer after routine treatment were treated with tamoxifen. Objective response rate (CR + PR) was 6.4%. 46.8% patients had stable disease with median time of...
6.
Pawlicki M, Rolski J, Wiczynska B, Rychlik U
Ginekol Pol
. 1998 Nov;
69(7):580-5.
PMID: 9810418
Twenty patients with advanced ovarian cancer were treated with chemotherapy PC (cisplatin 100 mg/m2, cyclophosphamide 1000 mg/m2) administered with amifostine. Sixty five percent of patients had objective response with 25%...
7.
Rolski J
Pol Merkur Lekarski
. 1997 May;
2(11):324-6.
PMID: 9377682
Several selected clinical prognostic factors were analyzed in the group of 253 patients suffering from lymphoma. Albumin serum level, performance status, Ann Arbor stage were found to be the important...
8.
Rolski J, Pawlicki M, Zemelka T, Pernal J
Pol Merkur Lekarski
. 1996 Oct;
1(4):271-3.
PMID: 9156943
The results of advanced breast cancer therapy with tamoxifen have been evaluated. The objective response to the drug has been achieved in 32 (31.7%) patients, and a 2-year survival in...
9.
Pawlicki M, Ziobro M, Rolski J, Koralewski P, Mirek T, Pernal J, et al.
Przegl Lek
. 1995 Jan;
52(7):344-6.
PMID: 8525001
The aim of the present study is the evaluation of late hematological complication in patients who received aggressive chemotherapy, and were observed 3, 5 and 10 years after treatment was...
10.
Rolski J, Koralewski P, Pawlicki M
Wiad Lek
. 1993 May;
46(9-10):356-9.
PMID: 8236992
In a group of 30 patients with the diagnosis of malignant non-Hodgkin lymphoma of high histological malignancy, a prospective randomized study was carried out concerning the effectiveness and toxicity of...